Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The receipt of this order further strengthens the company's position in the global pharmaceutical market
GV20 received an upfront payment and is eligible for additional milestone payments
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The fresh capital will propel Cordance into its first-in-human clinical trial
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Subscribe To Our Newsletter & Stay Updated